Military Personnel Sought to Share Blood Cancer Experience

The Institute of Medicine (IOM) and the U.S. Department of Veterans Affairs have determined that exposure to chemical and biological agents during World War II, Vietnam and the two Gulf Wars is associated with blood cancers. In response, IOM has identified the need to begin a special research program that addresses the needs of military personal and veterans.



The Leukemia & Lymphoma Society (LLS) and other blood cancer-related organizations have been seeking the creation of a dedicated, stand-alone blood cancer research program at DoD, but they need the help of military veterans who are also blood cancer survivors to share his or her story in an effort to gain more support in Congress for a blood cancer research program to be housed at DoD.



If you or a loved one is a military veteran, please contact Mark Pascu, national director, LLS Federal Affairs, at (202) 543-7033, ext. 7, or mark.pascu@lls.org.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap